[1] World Health Organization. Weekly epidemiological update on COVID-19-20 April 2022[EB/OL]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---20-april-2022.
[2] Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med,2022,386(6):509-520.
[3] Zhou S, Hill CS, Sarkar S, et al. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. J Infect Dis,2021,224(3):415-419.
[4] Harrison C. COVID-19 antiviral pills raise hopes for curbing pandemic. Nat Biotechnol,2021.
[5] US Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. Dec 22, 2021. https://www.fda.gov/media/155050/download.
[6] Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother,2008,42 7):1048-1059.
[7] Pfizer. Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death. Dec 14, 2021.https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results.
[8] Razonable RR, Ganesh R, Bierle DM. Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19. Mayo Clin Proc,2022,97(1):26-30.
[9] Rosoff PM, Patel KR, Scates A, et al. Coping with critical drug shortages: an ethical approach for allocating scarce resources in hospitals. Arch Intern Med,2012,172(19):1494-9.
[10] Centers for Disease Control and Prevention. The Possibility of COVID-19 after Vaccination: Breakthrough Infections. Dec 17, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html.
[11] Robertson E, Reeve KS, Niedzwiedz CL, et al. Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study. Brain Behav Immun,2021,94:41-50.
[12] Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet,2022,399(10332):1303-1312.
[13] National Institutes of Health. OpenData Portal: SARS-CoV-2 Variants and Therapeutics. Therapeutic activity explorer.B.1.1.529. Reported in vitro Therapeutic Activity. https://opendata.ncats.nih.gov/variant/activity.
[14] National Institutes of Health. COVID-19 treatment guidelines. The COVID-19 treatment guidelines panel's statement on the use of anti-SARS-CoV-2 monoclonal antibodies or remdesivir for the treatment of COVID-19 in nonhospitalized patients when omicron is the predominant circulating variant. Dec 30, 2021. https://files.covid19treatmentguidelines.nih.gov/guidelines/archive/statement-on-anti-sars-cov-2--12-23-2021.pdf.
[15] Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med,2022,386(4):305-315.
[16] European Medicines Agency. Assessment report. Procedure under article 5(3) of regulation (EC) No 726/2004 use of molnupiravir for the treatment of COVID-19. Nov 19, 2021. https://www.ema.europa.eu/en/documents/referral/lagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-assessment-report_en.pdf.
[17] GOV.UK. Medicines and Healthcare products Regulatory Agency. Summary of products characteristics for Lagevrio. Dec 20, 2021. https://www.gov.uk/government/publications/regulatory-approval-of-lagevrio-molnupiravir/summary-of-product-characteristics-for-lagevrio.
[18] US Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for lagevrio(molnupiravir). Dec 23, 2021. https://www.fda.gov/media/155054/download.
[19] GOV.UK. Medicines and Healthcare products Regulatory Agency. Regulatory approval of Paxlovid. Summary of products characteristics. Dec 31, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045762/Reg_SPC_PX_2_0_GB.pdf.
[20] UK National Health Service. Treatments for coronavirus (COVID-19). https://www.nhs.uk/conditions/coronavirus-covid-19/self-care-and-treatments-for-coronavirus/treatments-for-coronavirus. |
